Comparison between in vitro neutralization titres and in vivo protection against homologous and heterologous challenge induced by vaccines prepared from two serologically distinct variants of foot-and-mouth disease virus, serotype A22.
Guinea-pigs were challenged with homologous or heterologous strains of foot-and-mouth disease virus (FMDV) following vaccination with baby hamster kidney (BHK) monolayer cell-adapted or BHK suspension cell-adapted strains of FMDV serotype A22 Iraq 24/64. The protection afforded by these vaccines was analysed as a function of antigen dose and the in vitro serum virus neutralization titres achieved. The results show that the level of neutralizing antibody induced that afforded 50% protection was similar for both vaccines in homologous or heterologous challenge situations. However, although the dose of antigen required to achieve this titre against homologous virus was similar for the two vaccines, approximately 20-fold more of the suspension cell-adapted virus was required to elicit a protective titre against heterologous challenge compared to the dose of monolayer cell-adapted virus required. A synthetic peptide representing the amino acid sequence 135 to 167 of VP1, which is identical in the A22 Iraq 24/64 variant viruses, was shown to induce protection against both homologous and heterologous virus challenge.
Bolwell
C
C
Department of Virology, Wellcome Research Laboratories, Beckenham, Kent, U.K.
Parry
N R
NR
Rowlands
D J
DJ
D000818:Animals; D000910:Antibodies, Heterophile / Q000276:immunology; D005537:Aphthovirus / Q000276:immunology*; D002478:Cells, Cultured; D006224:Cricetinae; D005069:Evaluation Studies as Topic; D005536:Foot-and-Mouth Disease / Q000276:immunology* / Q000517:prevention & control; D010455:Peptides / Q000276:immunology; D011994:Recombinant Proteins / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology*; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000910:Antibodies, Heterophile; D010455:Peptides; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D014765:Viral Vaccines